No Data
Eli Lilly (NYSE:LLY) Unveils Positive Phase 2 Results For Heart Disease Therapy Amid 5% Share Dip
Eli Lilly's Cholesterol Drug Reduces Genetic Heart Disease Risk Factor By 93.9%
Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development
Eli Lilly and Co's drug has achieved positive clinical results and is expected to reduce the risk of hereditary cardiovascular diseases.
①Eli Lilly and Co announced that its small interfering RNA therapy, lepodisiran, achieved positive results in Phase II clinical research, with the highest dose reducing participants' lipoprotein a levels by an average of 93.9% over 60 to 180 days; ②Elevated lipoprotein a levels are a common risk factor for heart disease and are difficult to lower even with lifestyle changes, affecting about one-fifth of the global population.
Express News | Noom- Announced Agreement With Eli Lilly & Company's Lillydirect Pharmacy Provider, Gifthealth
Express News | Palatin Technologies Inc - Ind Applications Planned for 4Q25, Clinical Data Expected 1H26
